Universidade Estadual Paulista (UNESP), Faculdade de Medicina de Botucatu, Departamento de Especialidades Cir..rgicas e Anestesiologia, Botucatu, SP, Brazil.
Universidade Estadual Paulista (UNESP), Faculdade de Medicina de Botucatu, Departamento de Especialidades Cir..rgicas e Anestesiologia, Botucatu, SP, Brazil.
Braz J Anesthesiol. 2022 Nov-Dec;72(6):711-719. doi: 10.1016/j.bjane.2021.08.015. Epub 2021 Sep 23.
The influence of different crystalloid solutions infused during deceased-donor kidney transplant on the incidence of delayed graft function remains unclear. We investigated the influence of Plasma-Lyte.½ vs. 0.9% saline on the incidence of delayed graft function in deceased-donor kidney transplant recipients.
We conducted a single-blind randomized controlled trial of 104 patients aged 18 to 65 years who underwent deceased-donor kidney transplant under general anesthesia. Patients were randomly assigned to receive either Plasma-Lyte.½ (n.ß=.ß52) or 0.9% saline (n.ß=.ß52), at the same infusion volume, for intraoperative fluid replacement. The primary outcome was the occurrence of delayed graft function. Secondary outcomes included metabolic and electrolytic changes at the end of surgery.
Two patients in the Plasma-Lyte.½ group and one in the 0.9% saline group died postoperatively and were not included for analysis. The incidence of delayed graft function in Plasma-Lyte.½ and 0.9% saline groups were 60.0% (95% Confidence Interval [95% CI 46.2...72.4]) and 74.5% (95% CI 61.1...84.4), respectively (p.ß=.ß0.140). Mean (standard deviation) values of immediate postoperative pH and serum chloride levels in Plasma-Lyte.½ and 0.9% saline groups were 7.306 (0.071) and 7.273 (0.061) (p.ß=.ß0.013), and 99.6 (4.2) mEq.L and 103.3 (5.6) mEq.L, respectively (p.ß<.ß0.001). All other postoperative metabolic and electrolyte variables were not statistically different at the immediate postoperative period (p.ß>.ß0.05).
In deceased-donor kidney transplant recipients, the incidence of delayed graft function is not influenced by Plasma-Lyte.½ or 0.9% saline used for intraoperative fluid replacement.
在接受器官捐献者的肾移植过程中,不同晶体液的输注对延迟移植物功能的发生的影响尚不清楚。我们研究了使用 Plasma-Lyte.½ 与 0.9%生理盐水对接受器官捐献者的肾移植患者中延迟移植物功能发生的影响。
我们进行了一项单盲随机对照试验,纳入了 104 例年龄在 18 至 65 岁之间的患者,这些患者在全身麻醉下接受了器官捐献者的肾移植。患者被随机分配接受 Plasma-Lyte.½(n.ß=.ß52)或 0.9%生理盐水(n.ß=.ß52),输注量相同,用于术中液体替代。主要结局是延迟移植物功能的发生。次要结局包括手术结束时的代谢和电解质变化。
Plasma-Lyte.½ 组中有 2 例患者和 0.9%生理盐水组中有 1 例患者术后死亡,未纳入分析。Plasma-Lyte.½ 和 0.9%生理盐水组的延迟移植物功能发生率分别为 60.0%(95%置信区间 [95%CI] 46.2%至 72.4%)和 74.5%(95%CI 61.1%至 84.4%)(p.ß=.ß0.140)。Plasma-Lyte.½ 和 0.9%生理盐水组的即刻术后 pH 值和血清氯水平的平均值(标准差)分别为 7.306(0.071)和 7.273(0.061)(p.ß=.ß0.013)和 99.6(4.2)mEq.L 和 103.3(5.6)mEq.L(p.ß<.ß0.001)。在即刻术后期间,其他所有术后代谢和电解质变量均无统计学差异(p.ß>.ß0.05)。
在接受器官捐献者的肾移植患者中,使用 Plasma-Lyte.½ 或 0.9%生理盐水进行术中液体替代并不影响延迟移植物功能的发生。